EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern

Christophe Le Terrier iD, Patrice Nordmann, Chloé Buchs, Doris Yoong Wen Di, Gian Maria Rossolini, Roger Stephan, Mariana Castanheira iD, Laurent Poirel iD

Journal of Antimicrobial Chemotherapy · 05.09.2023 · 78 (9) · 2382-2384

DOI: 10.1093/jac/dkad210 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 03.07.2023. Verfasst von Christophe Le Terrier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Chemin du Musée 18, CH-1700 Fribo…. Hauptthemen laut MEDLINE: One Health, Borinic Acids. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, University of Fribourg, NARA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The increasing trend of carbapenem resistance observed in Gram-negative bacteria is mainly related to the dissemination of carbapenemase-encoding genes.1 A particular threat are those encoding MBLs, since production of MBLs leads to very limited treatment options.1 MBLs of the NDM group have been largely disseminated in human, animals and in the environment, making them the most frequently identified acquired carbapenemases worldwide.1,2 NDM-like β-lactamases hydrolyse all β-lactams (BLs) except monobactams, and are not inactivated by most of the recently developed β-lactamase inhibitors (BLIs) (avibactam, relebactam, vaborbactam, nacubactam or zidebactam).3 The newly developed cyclic boronate BLI, taniborbactam, alias VNRX-5313, is one of the few BLIs possessing significant inhibitory activity against MBLs, with the exception of IMP-like enzymes, and is currently in clinical development in combination with cefepime (https://clinicaltrials.gov/ct2/show/NCT03840148).4 Hence, the combination cefepime/taniborbactam displays excellent in vitro activity against NDM-producing Gram-negative isolates worldwide. However, using a panel of isogenic recombinant Escherichia coli strains producing a variety of MBLs, including NDM enzymes, we recently showed that NDM-9, differing from NDM-1 by a single amino acid substitution (E152K), was not inhibited by taniborbactam.5

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

One HealthBorinic AcidsGram-Negative BacteriaEnterobacteriaceaebeta-LactamasesAnti-Bacterial AgentsMicrobial Sensitivity TestsCarboxylic Acids

Substanzen

Borinic Acidsbeta-LactamasesAnti-Bacterial AgentstaniborbactamCarboxylic Acids

Autor:innen und Institutionen

  • Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Chemin du Musée 18, CH-1700 Fribourg, Switzerland.
  • Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland.
  • Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
  • Institute for Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • School of Earth Sciences and Environmental Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea.
  • Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy.

ORCID-Profile: Christophe Le Terrier, Mariana Castanheira, Laurent Poirel

Förderung

  • Swiss National Science Foundation
  • University of Fribourg
  • NARA

Zitieren

APA

Le Terrier, C., Nordmann, P., Buchs, C., Di, D. Y. W., Rossolini, G. M., Stephan, R., Castanheira, M., & Poirel, L. (2023). Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern. Journal of Antimicrobial Chemotherapy, 78(9), 2382-2384. https://doi.org/10.1093/jac/dkad210

Vancouver

Le Terrier C, Nordmann P, Buchs C, Di DYW, Rossolini GM, Stephan R, et al. Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern. Journal of Antimicrobial Chemotherapy. 2023;78(9):2382-2384. doi:10.1093/jac/dkad210

BibTeX
@article{LeTerrier2023,
  author = {Le Terrier, Christophe and Nordmann, Patrice and Buchs, Chloé and Di, Doris Yoong Wen and Rossolini, Gian Maria and Stephan, Roger and Castanheira, Mariana and Poirel, Laurent},
  title = {Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  volume = {78},
  number = {9},
  pages = {2382--2384},
  doi = {10.1093/jac/dkad210}
}
Kostenlos starten →